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Objective: To assess prospectively the association between the myomectomy route and fertility.
Design: Prospective cohort study.
Setting: The Comparing Treatments Options for Uterine Fibroids (COMPARE-UF) Study is a multisite national registry of eight clinic
centers across the United States.
Patient(s): Reproductive-aged women undergoing surgery for symptomatic uterine ﬁbroids.
Intervention(s): Not applicable.
Main Outcome Measure(s): We used life-table methods to estimate cumulative probabilities and 95% conﬁdence intervals (CI) of
pregnancy and live birth by the myomectomy route during 12, 24, and 36 months of follow-up (2015–2019). We also conducted
12-month interval-based analyses that used logistic regression to estimate odds ratios and 95% CIs for associations of interest. In
all analyses, we used propensity score weighting to adjust for differences across surgical routes.
Result(s): Among 1,095 women who underwent myomectomy (abdominal ¼ 388, hysteroscopic ¼ 273, and laparoscopic ¼ 434), 202
reported pregnancy and 91 reported live birth during 36 months of follow-up. There was little difference in the 12-month probability of
pregnancy or live birth by route of myomectomy overall or among women intending pregnancy. In interval-based analyses, adjusted
ORs for pregnancy were 1.28 (95% CI, 0.76–2.14) for hysteroscopic myomectomy and 1.19 (95% CI, 0.76–1.85) for laparoscopic
myomectomy compared with abdominal myomectomy. Among women intending pregnancy, adjusted ORs were 1.27 (95% CI,
0.72–2.23) for hysteroscopic myomectomy and 1.26 (95% CI, 0.77–2.04) for laparoscopic myomectomy compared with abdominal
myomectomy. Associations were slightly stronger but less precise for live birth.
Conclusion(s): The probability of conception or live birth did not differ appreciably by the myomectomy route among women observed
for 36 months postoperatively.
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terine ﬁbroids (UFs) are the leading indication for
hysterectomy in the United States (1, 2) and account
for more than $2.2 billion annually in health care
costs (3). Although the lifetime cumulative incidence of clinical diagnosis is approximately 30%, data from the standardized screening of women aged 35–49 years estimated a
cumulative incidence of ultrasound-detectable UFs by age
50 of >70% (4). Studies show a greater burden of UFs among
Black than white women, with disproportionately higher incidence, earlier ages at diagnosis and surgery, and more severe
symptoms at the time of initial diagnosis (4–7). Uterine ﬁbroid
symptoms include heavy menstrual bleeding, anemia, pain,
pelvic pressure, and genitourinary symptoms. The peak
incidence for UF symptoms occurs during the reproductive
years (7, 8) when many women are attempting pregnancy.
Given that Black women tend to experience earlier onset of
UFs and more severe disease, the impact of UFs on their
fertility may be greater.
Depending on their location within the uterus, UFs may
be associated with impaired fertility (9–12). However,
studies of UFs and fertility are inconsistent, and the
association may be due in part to uncontrolled or residual
confounding (e.g., by age), referral bias (13), or detection
bias (7, 14). Approximately 10% of pregnant women have
detectable UFs in the ﬁrst trimester (15), and UF presence
has been associated with spontaneous abortion in some
(16, 17) but not all studies (18). Furthermore, treatments for
UFs may affect fertility via adverse sequelae. In the United
States, health insurance typically covers UF treatment but
not infertility treatment; thus, UF treatment to improve
fertility is likely overused. However, research investigating
the extent to which fertility outcomes differ based on the
route of myomectomy is limited (19–22).
Myomectomy, the most common uterine-preserving procedure performed for UFs in the United States (23–30),
accounts for approximately 22% of all UF surgeries (30).
Considering inpatient and outpatient procedures in the
United States, the most common surgical route for
myomectomy is abdominal (via laparotomy; >75%),
followed by laparoscopic (with or without robotic
assistance) (approximately 15%) and hysteroscopic
(approximately 10%) routes (20, 30–33). According to data
from the American College of Surgeons National Surgical
Quality Improvement Program database, the percentage of
abdominal myomectomies increased by 11 percentage
points from 2012 to 2016 (while laparoscopic myomectomy
decreased), likely because of concerns about morcellation
and cancer (32, 34). Compared with laparoscopic
myomectomy, abdominal myomectomy has been associated
with longer hospitalizations, higher readmission rates, and
greater morbidity (31, 32).

U
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Abdominal myomectomy tends to be recommended more
commonly for patients who have larger uterine volume, multiple UFs, and UFs that cannot be removed easily by other
means. In contrast, laparoscopic myomectomy tends to be
recommended for women with smaller uterine volume and
subserosal/intramural UFs (31). Hysteroscopic myomectomy
is recommended for patients with symptomatic submucous
UFs. A 2020 review of surgical treatment of UFs for subfertility, including four randomized controlled trials with 442
participants, concluded that there was very low-quality
evidence on the association between surgical approach for
myomectomy and subsequent subfertility overall and by UF
location (20). Observational studies also have been limited
by small sample size, retrospective study design (which may
be prone to selection bias), inconsistency of results across
studies, and examination of only one type of surgical route
(11–13, 16, 19–21, 31, 35–45).
Prospective cohort studies that compare fertility success
across surgical approaches for myomectomy can ﬁll important gaps in the literature. In this report, we prospectively
examine the association between the route of myomectomy
(abdominal, hysteroscopic, and laparoscopic) for UFs and
the probability of conception and live birth during 36 months
of follow-up, censoring women with varying lengths of
follow-up and adjusting for potential confounding variables.
We hypothesize that the surgical route of myomectomy would
not be strongly associated with fertility outcomes after accounting for differences in patient and UF characteristics
across treatment groups. Evidence-based research is critical
to generate the information necessary for patients to choose
the surgical route for myomectomy that meets their individual
needs, goals, and preferences.

MATERIALS AND METHODS
The Comparing Treatments Options for Uterine Fibroids
(COMPARE-UF) Study is a multisite national registry of
women who were scheduled for treatment for symptomatic ﬁbroids at 1 of 8 clinic centers across the United States
(NCT02260752, clinicaltrials.gov): Mayo Clinic, INOVA
Health System, Brigham and Women’s Hospital, the University of Mississippi Medical Center, the University of California
Fibroid Network, Henry Ford Health System, the University of
Michigan, and the University of North Carolina between 2015
and 2019. Duke Clinical Research Institute (DCRI) served as
the Research Data and Coordinating Center. The primary
objective of the registry was to compare prospectively the
effectiveness of different surgical and interventional treatment options (hysterectomy, myomectomy, uterine artery
embolization) on patient-reported outcomes postoperatively
and during 3 years of follow-up using validated general and
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disease-speciﬁc surveys of quality of life. Details on the study
design, protocol, and rationale for COMPARE have been published previously (46). The registry protocol was reviewed and
approved by the Duke Institutional Review Board for the
coordinating center and by the review boards at each of the
clinical recruitment sites.
Trained site coordinators screened all women for eligibility. Eligible participants then provided informed consent
and Health Insurance Portability and Accountability Act
authorization, and completed an online baseline questionnaire through a secure, password-protected, web-based study
portal (SignalPath, LLC, Durham, NC) or through paper or
phone interviews with clinical site coordinators. The baseline
questionnaire elicited self-reported data on patient sociodemographics, medical history, ﬁbroid history, prior ﬁbroid procedures, current and prior ﬁbroid therapies, reproductive
history, measures of ﬁnancial distress, and childbearing
plans. Per protocol, the baseline questionnaire was completed
within the 30-day window before the procedure.
Follow-up questionnaires were completed 12, 24, and 36
months after the procedure. Participants completed questionnaires through the web-based portal, at in-person visits, or via
telephone interview with the Research Call Center at the DCRI.
The DCRI sent reminders to the participants to complete the
questionnaires. If a participant was lost to follow-up, coordinators at both the DCRI and the local recruitment sites attempted to contact the participant using medical records to
ascertain any new contact information.

Assessment of Uterine Characteristics and
Myomectomy
Myomectomy was performed according to professional standards and institutional protocols at each clinical site. The
choice of myomectomy and the surgical route was made independently of COMPARE-UF study protocols. The routes of
myomectomy examined in this study included abdominal,
hysteroscopic, and laparoscopic. Details about the surgery
were obtained from medical records. All participant records,
including pelvic imaging reports, were reviewed by a single
centralized team of abstractors to ensure consistency across
sites. Uterine ﬁbroids details were collected from the participants’ imaging reports, which included uterine dimensions
and the dimensions of each UF.

Assessment of Covariates
We collected self-reported data on sociodemographics at
baseline. These factors included age, self-identiﬁed race
(‘‘How would you best describe your race?’’ with response options: Black/African American, Asian, American Indian/
Alaska Native, Native Hawaiian/Paciﬁc Islander, White,
other), ethnicity (Hispanic/Latina, non-Hispanic Latina),
reproductive history (gravidity, parity), contraceptive history,
body mass index (kg/m2, calculated using self-reported height
and weight), marital status, educational level, and insurance
source. Additional baseline covariate data included clinical
factors, such as smoking status, comorbid conditions (e.g.,
diabetes, hypertension), gynecologic conditions (sexually
transmitted infections, abnormal cervical cytology, polycystic ovarian syndrome), mental health history, and history
of prior medical and surgical therapies for UFs. Uterine and
UF characteristics at baseline, including UF size, number,
location, and uterine volume (cm3), were derived from the
pretreatment imaging reports.
On the baseline and annual follow-up questionnaires
through 36 months, participants were asked about their intentions for pregnancy, speciﬁcally whether they were ‘‘trying to
get pregnant now.’’ If not, women were asked, ‘‘Are you planning to become pregnant in the future?’’ with response options of ‘‘Yes, likely within the next 2 years,’’ ‘‘Would like to
keep as an option,’’ and ‘‘No.’’ To ascertain infertility history,
the baseline questionnaire included the question: ‘‘Did you
ever try for more than one year to get pregnant?’’ All
follow-up questionnaires included the question: ‘‘Have you
been trying to get pregnant for a year or more?’’ At all time
points (baseline and follow-up), participants completed the
Patient Health Questionnaire-2, a two-item measure to screen
for clinical depression (47, 48); the Menopause Rating Scale, a
measure of climacteric symptoms (49, 50); the UF Symptomquality of life, a disease-speciﬁc instrument that assesses
symptom severity and health-related quality of life in women
with UFs (51), and the visual analog scale, which is a
validated, subjective measure for acute and chronic pain
(0 ¼ ‘‘no pain’’ and 100 ¼ ‘‘worst pain’’). The postprocedure
survey, completed within 11–18 months after the procedure,
collected information about the time to resumption of usual
activities, interim hospitalizations, procedural complications,
and incidental cancer diagnoses.

Exclusions
Assessment of Fertility and Pregnancy Outcomes
On annual follow-up questionnaires from 12–36 months
postprocedure, women were asked: ‘‘In the past year, have
you had any pregnancies?’’ Those who responded ‘‘yes’’
were then asked about the number of pregnancies and the
outcome of each pregnancy (up to 3 pregnancies), with the
following response options: ‘‘pregnant and not yet delivered,’’
‘‘delivered a single baby,’’ ‘‘delivered twins,’’ ‘‘delivered triplets,’’ ‘‘miscarriage (also known as spontaneous abortion),’’
‘‘elective or therapeutic abortion,’’ ‘‘stillbirth,’’ or ‘‘tubal or
ectopic pregnancy.’’ We did not ascertain whether pregnancies were achieved with the use of assisted reproductive
technologies.

The present analysis included all COMPARE-UF eligible patients enrolled from December 28, 2015 through December
17, 2019. We excluded participants who underwent a procedure other than myomectomy because other treatments may
have been contraindicated for patients desiring future fertility.
Furthermore, we excluded participants who received myomectomy but had missing data on the surgical route (Supplemental
Figure 1, available online). The ﬁnal analytic sample for analysis was 1,095 participants: 388 who underwent abdominal
myomectomy, 273 who underwent hysteroscopic myomectomy, and 434 who underwent laparoscopic myomectomy.
All sites recruited women in each of these groups, with the
site-speciﬁc myomectomy percentages ranging from 19.2%
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(University of Mississippi Medical Center) to 71.7% (University of California Fibroid Network).

Statistical Analysis
We assessed prospectively the association between the
surgical route for myomectomy (abdominal, hysteroscopic,
laparoscopic) and self-reported pregnancy and live birth in
each 12-month interval during 36 months of follow-up
(2015–2019). We compared sociodemographic and clinical
factors between the myomectomy surgical route groups. Our
primary events of interest were the time from index procedure
to the occurrence of ﬁrst pregnancy and ﬁrst live birth during
the follow-up period. Time was measured as 12, 24, or 36
months corresponding to ﬁrst, second, or third annual
follow-up, respectively. Because of the observational design
of COMPARE, we used inverse propensity weighting methods,
speciﬁcally overlap weighting, to adjust for confounding
(52, 53). The propensity score (probability of surgical route
for myomectomy) was estimated using a multinomial regression model with the myomectomy route as the dependent variable and participant characteristics considered to be potential
confounders as independent variables. Potential confounders
for inclusion in the propensity model were identiﬁed a priori
based on a review of the literature, clinical experience, and the
drawing of a causal diagram. These included age, race/
ethnicity, number of prior UF procedures, body mass index,
history of polycystic ovary syndrome, contraception (combined oral contraception, progestin-only oral contraception,
patch, vaginal ring, implant, hormone-containing intrauterine device, progestin-only injectable), number of children
(0, 1, R2), fertility intent (currently trying; not currently
trying but intending to try within 2 years; not currently trying
but intending to try in the future; not interested in future
pregnancy), history of difﬁculty becoming pregnant, and
uterine volume. In sensitivity analyses, we further adjusted
for the largest UF volume and UFs with a submucous location.
We did not consider the ‘‘number of UF’’ in the propensity
score because of incomplete data on this variable. Covariates
with missing data at baseline were imputed using the fully
conditional speciﬁcation method in SAS PROC MI (54), using
all patient-reported variables available in the COMPARE-UF
database (46). Given the low percentage of missing data for
any given covariate (<5%), we used a single imputation
data set in this analysis, consistent with previous publications
from this registry and prior sensitivity analyses that showed
no difference using multiple imputation.
First, we used life-table methods with propensity score
weighting to estimate the probabilities of pregnancy and
live birth and 95% conﬁdence intervals (CIs) in each time interval (0–12 months, 0–24 months, or 0–36 months) after accounting for censoring. Women were censored at the ﬁrst
occurrence of any of the following events: report of natural
or surgical menopause, loss to follow-up, or end of followup (36 months). We then conducted a 12-month intervalbased analysis that updated pregnancy intent annually and
used logistic regression to estimate odds ratios (ORs) and
95% CIs for the association between myomectomy routes
and annual outcomes of conception and live birth. The unit
4

of analysis was study time (person-years). The analysis pooled
results across all intervals. We included a ﬁxed effect for
treatment and used propensity score weighting to create comparable groups by the procedure. In addition, we repeated analyses in subgroups restricted by pregnancy intent: actively
trying to conceive or intending to conceive within the next
2 years. Potential correlation between patients from the
same clinical center was handled by ﬁtting a robust empirical
variance estimator, with clustering by the clinical center.
We performed sensitivity analyses that excluded women
with hysteroscopic myomectomy as a comparison group,
owing to the large differences in patient and UF characteristics between these participants and all other participants. This
involved rerunning the propensity score weighting to balance
the UF characteristics across the abdominal and laparoscopic
myomectomy groups, the life-table analyses, and logistic
regression models for associations with pregnancy and live
birth. We conducted a subsequent sensitivity analysis to account for additional UF characteristics: maximum UF volume
and submucous location. These variables were not included in
the primary propensity model because their method of collection was not standardized across clinical sites, and they were
thought to be captured less accurately than uterine volume.
All analyses were conducted using SAS software (SAS Institute, Cary, NC).

RESULTS
Baseline Sociodemographic and Clinical
Characteristics
There were no appreciable differences in the percentages
lost to follow-up by the myomectomy group (data not
shown). Participants who underwent abdominal myomectomy tended to be younger, nulliparous, have a larger
uterine volume at surgery, larger maximum UF volume,
and were more likely to identify as Black or African American than women who underwent other routes of myomectomy (Table 1). Participants who underwent abdominal
myomectomy were also more likely to be currently trying
(29.1%) or intending to conceive within the next 2 years
(32.3%), relative to the other routes of myomectomy. Hysteroscopic myomectomy patients were substantially more
likely than the other two myomectomy groups to have
R2 prior UF procedures. There was little difference in
the history of infertility across the 3 groups. Likewise,
the groups were not notably different with respect to UF
Symptom-quality of life (UFS-QOL), EuroQOL scale, or visual analog scale scores. Comparability between the treatment groups was achieved at baseline after propensity
weighting (data not shown).

Probabilities of Pregnancy and Live Birth, Overall
and by Myomectomy Route
Among 1,095 women who underwent myomectomy, 202 reported pregnancy, and 91 reported live birth during followup; some of these women were still pregnant at the end of
follow-up. There was no appreciable difference in the probability of pregnancy or live birth by the route of myomectomy
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TABLE 1
Baseline characteristics of COMPARE-UF participants by surgical route of myomectomy.
Myomectomy route
Characteristic

Abdominal

Laparoscopic

Hysteroscopic

Total

No. of women
Age (years), mean (SD)
%30
31–39
40–44
R45
Race
Black or African American
White
Other
Hispanic or Latina
Body mass index (kg/m2), mean (SD)
History of polycystic ovary syndrome
Contraception to prevent pregnancy
Combined oral contraception, patch, or ring
Progestin-only implant
Progestin-only oral contraception
Hormone-containing intrauterine device
Progestin-only injectable
Fertility planning status
Currently trying
Not currently trying, but within 2 years
Not currently trying, but keeping option open for future
Not currently trying, not interested in future pregnancy
Parity (no. of births)
0
1
R2
History of difﬁculty conceiving
Fibroid characteristics:
No. of prior ﬁbroid procedures
0
1
R2
Uterine volume (cm3), mean (SD)
Maximum ﬁbroid volume (cm3), mean (SD)
Any submucous ﬁbroid
Yes
No/missinga
UFS-QOL, mean (SD)
Concern
Activities
Energy/mood
Control
Self-conscious
Sexual function
Total summary of 6 subscale scores above
Symptom severity
EQ-5-Dimension Scale (% without problems)
Mobility
Self-care
Usual activities
Pain/discomfort
Anxiety/depression
Visual analog pain scale (0–100), mean (SD)

388
36.8 (5.7)
49 (12.6%)
218 (56.2%)
85 (21.9%)
36 (9.3%)

434
37.3 (5.9)
53 (12.2%)
227 (52.3%)
103 (23.7%)
51 (11.8%)

273
40.9 (7.2)
25 (9.2%)
88 (32.2%)
73 (26.7%)
87 (31.9%)

1,095
38.0 (6.4)
127 (11.6%)
533 (48.7%)
261 (23.8%)
174 (15.9%)

198 (51.0%)
118 (30.4%)
72 (18.6%)
27 (7.0%)
29.0 (7.1)
23 (6.1%)

154 (35.8%)
188 (43.7%)
88 (20.5%)
21 (5.0%)
27.7 (7.2)
26 (6.2%)

104 (38.2%)
127 (46.7%)
41 (15.1%)
29 (10.9%)
30.0 (8.9)
14 (5.1%)

456 (41.8%)
433 (39.7%)
201 (18.4%)
77 (7.2%)
28.7 (7.7)
63 (5.9%)

38 (9.8%)
18 (4.6%)
23 (5.9%)
19 (4.9%)
20 (5.2%)

24 (5.5%)
8 (1.8%)
11 (2.5%)
7 (1.6%)
8 (1.8%)

23 (8.4%)
8 (2.9%)
6 (2.2%)
6 (2.2%)
9 (3.3%)

85 (7.8%)
34 (3.1%)
40 (3.7%)
32 (2.9%)
37 (3.4%)

113 (29.1%)
125 (32.2%)
109 (28.1%)
41 (10.6%)

124 (28.6%)
116 (26.7%)
104 (24.0%)
87 (20.0%)

52 (19.0%)
41 (15.0%)
46 (16.8%)
133 (48.7%)

289 (26.4%)
282 (25.8%)
259 (23.7%)
261 (23.8%)

315 (81.2%)
46 (11.9%)
27 (7.0%)
101 (27.1%)

335 (77.2%)
62 (14.3%)
37 (8.5%)
117 (28.0%)

143 (52.4%)
43 (15.8%)
87 (31.9%)
68 (25.2%)

793 (72.4%)
151 (13.8%)
151 (13.8%)
286 (27.0%)

317 (81.7%)
66 (17.0%)
5 (1.3%)
912.8 (737)
483.5 (743.4)

371 (85.5%)
52 (12.0%)
11 (2.5%)
486.4 (390)
265.3 (313.6)

215 (78.8%)
49 (18.0%)
9 (43.3%)
265.6 (275)
72.9 (425.9)

903 (82.5%)
167 (15.3%)
25 (2.3%)
580.5 (585)
295.2 (552.2)

105 (27.1%)
283 (72.9%)

96 (22.1%)
338 (77.9%)

172 (63.0%)
101 (37.0%)

373 (34.1%)
722 (65.9%)

47.1 (32.2)
52.7 (28.8)
50.3 (27.7)
48.7 (27.0)
39.8 (31.6)
54.3 (34.8)
49.5 (25.8)
51.6 (25.6)

52.6 (33.9)
56.3 (29.2)
52.8 (28.3)
51.7 (27.6)
50.2 (31.6)
55.9 (33.7)
53.4 (25.9)
48.6 (23.9)

37.2 (28.4)
50.0 (29.1)
49.2 (27.9)
48.8 (26.8)
52.7 (32.7)
49.8 (35.7)
47.3 (26.0)
54.4 (24.6)

46.8 (32.6)
53.5 (29.1)
51.0 (28.0)
49.9 (27.2)
47.3 (32.3)
53.8 (34.7)
50.6 (26.0)
51.1 (24.8)

314 (81.6%)
365 (95.1%)
250 (65.1%)
80 (20.8%)
156 (40.7%)
72.5 (19.9)

378 (87.7%)
416 (96.7%)
287 (66.9%)
108 (25.1%)
163 (38.0%)
74.7 (16.7)

228 (83.8%)
255 (93.4%)
192 (70.3%)
101 (37.0%)
112 (41.2%)
73.3 (18.2)

920 (84.6%)
1036 (95.3%)
729 (67.1%)
289 (26.5%)
431 (39.8%)
73.6 (18.3)

UFS-QOL ¼ Uterine Fibroid Symptom and Quality of Life subscale, EQ ¼ EuroQOL scale.
a
Unable to distinguish ‘‘no’’ from ‘‘missing’’ because of lack of standardization and inconsistent reporting of imaging data across clinical sites.
Wise. Route of myomectomy and fertility. Fertil Steril 2022.

overall, among women intending pregnancy within 2 years or
among women actively trying to conceive (Table 2).
Among women who had a myomectomy, the strongest
predictors of reported conception were age and pregnancy
intent at baseline (data not shown). Among women who

reported currently trying to conceive at baseline, the cumulative probabilities of pregnancy within the ﬁrst year of followup for women aged %30, 31–39, 40–44, and R45 years were:
0.37 (95% CI, 0.24–0.47), 0.29 (95% CI, 0.23–0.35), 0.16 (95%
CI, 0.09–0.22), and 0.14 (95% CI, 0.03–0.23). After 3 years,
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Cumulative probability of pregnancy and live birth during follow-up, by myomectomy route.a
Probability of pregnancy (95% CI) by follow-up time

Myomectomy
Route
Abdominal
Hysteroscopic
Laparoscopic

Subgroup

Pregnancies/total women (%)

12 months

24 months

36 months

All women
Trying to conceive or intending to conceive within the next 2 yearsb
Trying to conceiveb
All women
Trying to conceive or intending to conceive within the next 2 yearsb
Trying to conceiveb
All women
Trying to conceive or intending to conceive within the next 2 yearsb
Trying to conceiveb

69/388 (17.8%)
64/238 (26.9%)
36/113 (31.9%)
37/273 (13.6%)
34/94 (36.2%)
22/53 (41.5%)
96/434 (22.1%)
88/241 (36.5%)
60/125 (48.0%)

0.13 (0.08–0.14)
0.25 (0.17–0.34)
0.28 (0.18–0.42)
0.16 (0.11–0.22)
0.26 (0.17–0.38)
0.36 (0.24–0.53)
0.16 (0.13–0.19)
0.28 (0.21–0.35)
0.40 (0.30–0.52)

0.20 (0.16–0.25)
0.37 (0.27–0.48)
0.41 (0.28–0.57)
0.24 (0.17–0.32)
0.41 (0.29–0.55)
0.48 (0.33–0.66)
0.24 (0.20–0.29)
0.40 (0.32–0.49)
0.54 (0.42–0.67)

0.24 (0.19–0.30)
0.45 (0.33–0.59)
0.47 (0.30–0.66)
0.33 (0.23–0.45)
0.56 (0.40–0.74)
0.63 (0.42–0.83)
0.27 (0.23–0.34)
0.50 (0.38–0.62)
0.67 (0.50–0.83)

Subgroup

Live births/total women (%)

12 months

24 months

36 months

All women
Trying to conceive or intending to conceive within the next 2 yearsb
Trying to conceiveb
All women
Trying to conceive or intending to conceive within the next 2 yearsb
Trying to conceiveb
All women
Trying to conceive or intending to conceive within the next 2 yearsb
Trying to conceiveb

28/388 (7.2%)
26/238 (10.9%)
16/113 (14.2%)
19/273 (7.0%)
17/94 (18.1%)
10/53 (18.9%)
44/434 (10.1%)
39/241 (16.2%)
22/125 (17.6%)

0.01 (0.00–0.05)
0.01 (0.00–0.07)
0.02 (0.00–0.12)
0.04 (0.02–0.08)
0.05 (0.02–0.14)
0.06 (0.02–0.19)
0.02 (0.01–0.05)
0.03 (0.01–0.08)
0.03 (0.01–0.10)

0.10 (0.06–0.17)
0.20 (0.12–0.32)
0.25 (0.14–0.43)
0.13 (0.08–0.21)
0.21 (0.12–0.35)
0.27 (0.14–0.48)
0.12 (0.08–0.17)
0.20 (0.13–0.29)
0.26 (0.15–0.41)

0.10 (0.06–0.17)
0.20 (0.12–0.32)
0.25 (0.14–0.43)
0.19 (0.12–0.30)
0.31 (0.18–0.50)
0.30 (0.16–0.52)
0.14 (0.10– 0.21)
0.25 (0.16–0.37)
N/A (no data)

Probability of live birth (95% CI) by follow-up time

Myomectomy
Route
Abdominal
Hysteroscopic
Laparoscopic

CI ¼ conﬁdence interval.
a
Cumulative probability accounts for censoring using life-table methods and adjusts for confounding using propensity score weights.
b
Based on self-report at baseline only.
Wise. Route of myomectomy and fertility. Fertil Steril 2022.
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TABLE 3
Myomectomy route in relation to pregnancy and live birth, interval-based analysis.
All women

Adjusteda

Unadjusted

Myomectomy
route

No. of
events/total (%)

OR

95% CI

OR

Abdominal
Hysteroscopic
Laparoscopic

69/388 (17.8%)
37/273 (13.6%)
96/434 (22.1%)

1.00
0.81
1.38

Reference
0.52, 1.24
0.98, 1.94

1.00
1.28
1.19

Abdominal
Hysteroscopic
Laparoscopic

28/388 (7.2%)
19/273 (7.0%)
44/434 (10.1%)

1.00
1.03
1.47

Reference
0.57, 1.86
0.90, 2.39

1.00
1.66
1.38

Adjusted and restricted to women with pregnancy intenta,b

95% CI
Pregnancy
Reference
0.76, 2.14
0.76, 1.85
Live birth
Reference
0.80, 3.43
0.72, 2.62

OR

95% CI

1.00
1.27
1.26

Reference
0.72, 2.23
0.77, 2.04

1.00
1.71
1.49

Reference
0.81, 3.65
0.77, 2.89

Abbreviations: OR ¼ odds ratio, CI ¼ conﬁdence interval.
a
Applies propensity score weights to account for differences in demographics, symptoms, and ﬁbroid characteristics.
b
Restricted to women with fertility intent (actively trying to conceive or intending to conceive within the next 2 years) at the beginning of the 12-month interval (time-varying covariate).
Wise. Route of myomectomy and fertility. Fertil Steril 2022.

those respective cumulative probabilities of pregnancy
increased to: 0.67 (95% CI, 0.48–0.79), 0.57 (95% CI, 0.47–
0.65), 0.34 (95% CI, 0.21–0.45), and 0.30 (95% CI, 0.08–
0.47). This statistical model had a Harrell’s C-index of 0.80
(55), indicating very good prediction. Other variables in this
model that did not appreciably improve prediction included
myomectomy route, use of contraception at baseline, number
of prior UF procedures, parity, and infertility history.

abdominal myomectomy. Associations were stronger but
less precise for live birth.
When we repeated analyses after excluding women with
hysteroscopic myomectomy and derived new propensity
weights to account for patient and UF differences across laparoscopic vs. abdominal myomectomy, the results were similar
when comparing these two surgical approaches (Table 4).
Additional adjustment for maximum UF size and submucous
UFs also yielded consistent ﬁndings (Table 4).

DISCUSSION

ORs of Pregnancy and Live Birth, by Myomectomy
Route

In this prospective analysis of COMPARE-UF participants
undergoing myomectomy for symptomatic UFs, there was
little association between the surgical route for myomectomy and the probability of conception during a 36-month
follow-up period, after adjusting for patient demographics,
reproductive history, and uterine volume. Associations
with live birth were stronger but less precise due to small
numbers. Among myomectomy patients, the strongest predictors of pregnancy success were age and pregnancy intent
at baseline. Among women who reported currently trying to
conceive at baseline, the cumulative probabilities of pregnancy during 3 years of follow-up, after accounting for

Overall, adjusted ORs for pregnancy were 1.28 (95% CI, 0.76–
2.14) for hysteroscopic myomectomy and 1.19 (95% CI, 0.76–
1.85) for laparoscopic myomectomy compared with
abdominal myomectomy (Table 3). There was evidence of
substantial confounding by patient and UF characteristics,
as evidenced by the attenuation of unadjusted ORs after
adjustment for confounding using propensity weighting.
Among women intending pregnancy, ORs were 1.27 (95%
CI, 0.72–2.23) for hysteroscopic myomectomy and 1.26 (95%
CI, 0.77–2.04) for laparoscopic myomectomy compared with

TABLE 4
Myomectomy route (laparoscopic vs. abdominal) in relation to pregnancy and live birth during follow-up, interval-based analysis.
Adjusteda

Unadjusted

Myomectomy
route

OR

95% CI

OR

95% CI

OR

Abdominal
Laparoscopic

1.00
1.38

Reference
0.98, 1.94

1.00
1.15

Reference
0.81, 1.66

1.00
1.14

Abdominal
Laparoscopic

1.00
1.47

Reference
0.90, 2.39

1.00
1.32

Reference
0.79, 2.19

1.00
1.24

c

Adjusted and restricted to women with pregnancy intenta,b
c

95% CI

Pregnancy
Reference
0.79, 1.64
Live birth
Reference
0.75, 2.06

OR

95% CI

ORc

95% CIc

1.00
1.25

Reference
0.85, 1.84

1.00
1.25

Reference
0.84, 1.84

1.00
1.42

Reference
0.84, 2.39

1.00
1.35

Reference
0.80, 2.25

Abbreviations: OR ¼ odds ratio, CI ¼ conﬁdence interval.
a
Applies propensity score weights to account for differences in demographics, symptoms, and ﬁbroid characteristics.
b
Restricted to women with fertility intent (actively trying to conceive or intending to conceive within the next 2 years) at the beginning of the 12-month interval (time-varying covariate).
c
Propensity score weights augmented by maximum ﬁbroid volume and the presence of at least one submucous ﬁbroid.
Wise. Route of myomectomy and fertility. Fertil Steril 2022.
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varying lengths of follow-up using life-table methods, were
as high as 67% among women aged 30 or younger and 30%
among women aged R45 years. The model with age and
pregnancy intent showed excellent predictive probability
for pregnancy (80%); after accounting for age and pregnancy intent, the myomectomy route was not an important
predictor of pregnancy. These results contribute to the sparse
literature on the inﬂuence of the surgical route of myomectomy and fertility outcomes.
Large differences in pretreatment patient characteristics
were observed across the different routes of myomectomy.
These differences are not surprising given that procedures
like abdominal myomectomy are typically recommended for
women with larger uterine volumes and larger and more
numerous UFs. Although we successfully adjusted for many
of the observed differences using propensity weighting, this
approach includes assumptions that may not fully capture
the severity of UF characteristics among women who underwent abdominal myomectomy (e.g., setting the mean uterine
volume to 300 cm3 for all subtypes of myomectomy, even
though the mean volume for all women with abdominal myomectomy was approximately 900 cm3). To increase the generalizability of our ﬁndings, we repeated our analyses after
excluding women with hysteroscopic myomectomy, for
whom UF disease severity would be lower relative to women
undergoing abdominal or laparoscopic myomectomy. The analyses restricted to abdominal and laparoscopic myomectomy
focused on treatments with better covariate overlap. Such a
comparison would better emulate the real-life situation where
a given patient might be eligible for abdominal or laparoscopic myomectomy, but not hysteroscopic myomectomy.
Again, these results showed little evidence for a difference
in pregnancy comparing abdominal and laparoscopic myomectomy surgical routes. Thus, our results indicated that
the choice of abdominal vs. laparoscopic myomectomy for
women with UFs that cannot be treated appropriately via
the hysteroscopic route can be based on other considerations
besides future fertility.
Although myomectomy is the treatment of choice for
women desiring to preserve their fertility (24–29) and is
performed frequently among women with unexplained
infertility or recurrent spontaneous abortion, its effect on
subsequent fertility is unclear (11–13, 16, 20, 21, 35–43).
One study reported that the surgical route of myomectomy
had little effect on fertility outcomes (44), but other studies
have not directly compared the surgical routes of
myomectomy (19, 31, 45). One difﬁculty in comparing
outcomes in nonrandomized participants is that important
factors associated with pregnancy outcomes, particularly
age and UF characteristics, may differ between groups
before treatment (56, 57). For example, a recent study
reported that women with >6 UFs removed were less likely
to conceive; however, it was unclear whether this was
related to the severity of UFs itself or to the surgical
procedure (19). Moreover, nonpatient factors, including the
skill of the surgeon and the availability and/or use of
assisted reproductive technology after UF treatment may
have inﬂuenced study outcomes as well.
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The strengths of the analysis include the prospective
design, 3-year follow-up period, relatively large sample
size, availability of pretreatment medical and operative notes,
detailed covariate information, and application of validated
propensity weighting methods to account for differences in
pretreatment characteristics (e.g., uterine anatomy—overall
uterine size; number, size, and location of individual UF).
There are limited comparative data on fertility outcomes
among women undergoing myomectomy, and thus, observational studies that are prospective in design can make an
important contribution to the literature.
The limitations of the study include the restriction of analyses to women undergoing myomectomy only and the potential unmeasured differences in the distribution of uterine
anatomy characteristics across myomectomy procedures,
which could have introduced residual confounding by indication. However, sensitivity analyses that included additional
UF characteristics in the propensity score (e.g., location and
size of largest UF) had little impact on the results. To the
extent that confounding was not properly accounted for, we
might expect to observe lower fertility success among women
undergoing abdominal myomectomy relative to the other
types of myomectomy because women offered abdominal
myomectomy tend to have more severe disease (e.g., larger
and more numerous UFs; submucous UFs that could be
more strongly associated with inhibition of implantation)
(7, 8). Many of the demographic characteristics that are
more common among women with severe UFs (e.g., later
reproductive age, African ancestry) are also risk factors for
adverse reproductive outcomes, such as infertility and spontaneous abortion (58, 59), and could confound the potential
association between the myomectomy route and these outcomes (7). This, in turn, limits our ability to compare fertility
across different treatments. As mentioned above, propensity
weighting may have made the results less generalizable to
women with more severe UFs who undergo abdominal myomectomy. Whether it is even appropriate to compare abdominal with laparoscopic and hysteroscopic myomectomy is
debatable given that a single patient may never be offered
all three of these options. However, the extent to which differences in preoperative uterine anatomy or other UF characteristics alone, independent of the route of procedure, would
have had a direct effect on the fertility outcomes is unclear.
Lack of data on speciﬁc types of reproductive failures, such
as fertilization, implantation, or postimplantation losses, precluded the examination of potential mechanisms. We did not
have data on whether women used fertility treatments to
conceive or whether they conceived spontaneously, and differences in these factors may have obscured the differences
in fertility success across myomectomy route (60–64).
The COMPARE-UF data were collected from a convenience sample of patients undergoing UF procedures at
several clinical sites across the United States; thus, the prevalence of myomectomy subtypes in this population is not
representative of the general population. The primary eligibility criterion for inclusion in the COMPARE-UF registry
was the presence of symptomatic UFs, including subfertility
as a syndrome. The proportion of women undergoing
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hysteroscopic resection reﬂects the distribution of women
with UFs suitable for hysteroscopic resection among our study
population, most of whom were not actively trying to get
pregnant. We also note that live birth rates were partly limited
by varying lengths of follow-up. If patients were advised to
wait 4–6 months postprocedure before attempting to conceive
and had average fecundability, the ﬁrst births would not take
place until after 12 months of follow-up.
Another important limitation is that we relied on clinical
imaging and operative reports at participating clinical sites
to characterize the location of the UF being removed. Although
reports were abstracted using a standard form that included
data on the International Federation of Gynecology and Obstetrics (FIGO) stage, fewer than 2% of COMPARE-UF reports
used the FIGO classiﬁcation. The general categorization of
UFs into submucous, intramural, and subserosal has been in
practice for several decades, and there is some clinical and
some basic science evidence to indicate that submucous UFs
are more likely to contribute to infertility given their ability
to cause uterine cavity distortion (11). There is also evidence
that the removal of submucous UFs increases subsequent pregnancy rates (11). However, controversy remains about the role
of intramural UFs in the pathogenesis of infertility (65). In a
recently-published debate (65), experts cited several mechanisms by which intramural UFs could inﬂuence fertility,
including impaired endometrial and myometrial blood supply,
reduced endometrial receptivity, greater myometrial contractility, thickening of the UF capsule, and hormonal and genetic
alterations, all of which favored the removal of intramural UFs
to improve fertility. Other experts argued against the removal
of intramural UFs to improve fertility, citing concerns about
surgical complications and challenges in the interpretation of
published studies because of methodologic issues, such as confounding, biologic heterogeneity (e.g., driver mutations; FIGO
type 3 vs. 4), and selection bias related to differential referral
patterns and insurance coverage for UF care (65–68).
Conversely, there is general agreement that subserosal UFs
have a limited, if any, impact on fertility although data are
also limited, particularly for larger UFs (11). Finally,
comparing fertility in women with intramural UFs
surrounded by myometrium (FIGO type 4) with those that
contact the endometrium (FIGO type 3) is a novel area of
investigation (65, 66), but was beyond the scope of this report.
Results from the present study indicated that the probability of pregnancy or live birth during 36 months of follow-up
did not differ appreciably according to the surgical route of
myomectomy, particularly when comparing abdominal vs.
laparoscopic routes, after accounting for pretreatment differences in patient characteristics. Additional follow-up may be
needed to determine if the similarity in fertility outcomes
across myomectomy groups persists over time. If conﬁrmed,
our results provide little reason for a change in how the current
myomectomy route is chosen by patients in consultation with
their providers in regard to a patient’s desire for future fertility.
DIALOG: You can discuss this article with its authors and
other readers at https://www.fertstertdialog.com/posts/
33426

REFERENCES
1.
2.
3.
4.

5.

6.

7.
8.
9.
10.

11.
12.

13.

14.

15.

16.

17.

18.

19.

20.
21.

22.
23.
24.
25.

Wilcox LS, Koonin LM, Pokras R, Strauss LT, Xia Z, Peterson HB. Hysterectomy in the United States, 1988-1990. Obstet Gynecol 1994;83:549–55.
Farquhar CM, Steiner CA. Hysterectomy rates in the United States 19901997. Obstet Gynecol 2002;99:229–34.
Flynn M, Jamison M, Datta S, Myers E. Health care resource use for uterine
ﬁbroid tumors in the United States. Am J Obstet Gynecol 2006;195:955–64.
Baird DD, Dunson DB, Hill MC, Cousins D, Schectman JM. High cumulative
incidence of uterine leiomyoma in Black and White women: ultrasound evidence. Am J Obstet Gynecol 2003;188:100–7.
Marshall LM, Spiegelman D, Barbieri RL, Goldman MB, Manson JE,
Colditz GA, et al. Variation in the incidence of uterine leiomyoma among
premenopausal women by age and race. Obstet Gynecol 1997;90:967–73.
Kjerulff KH, Langenberg P, Seidman JD, Stolley PD, Guzinski GM. Uterine
leiomyomas. Racial differences in severity, symptoms and age at diagnosis.
J Reprod Med 1996;41:483–90.
Wise LA, Laughlin-Tommaso SK. Epidemiology of uterine ﬁbroids: from
menarche to menopause. Clin Obstet Gynecol 2016;59:2–24.
Laughlin SK, Schroeder JC, Baird DD. New directions in the epidemiology of
uterine ﬁbroids. Semin Reprod Med 2010;28:204–17.
Whynott RM, Vaught KCC, Segars JH. The effect of uterine ﬁbroids on infertility: a systematic review. Semin Reprod Med 2017;35:523–32.
Metwally M, Farquhar CM, Li TC. Is another meta-analysis on the effects of
intramural ﬁbroids on reproductive outcomes needed? Reprod Biomed Online 2011;23:2–14.
Pritts EA, Parker WH, Olive DL. Fibroids and infertility: an updated systematic
review of the evidence. Fertil Steril 2009;91:1215–23.
Sunkara SK, Khairy M, El-Toukhy T, Khalaf Y, Coomarasamy A. The effect of
intramural ﬁbroids without uterine cavity involvement on the outcome of IVF
treatment: a systematic review and meta-analysis. Hum Reprod 2010;25:
418–29.
Johnson G, MacLehose RF, Baird DD, Laughlin-Tommaso SK, Hartmann KE.
Uterine leiomyomata and fecundability in the Right from the Start study.
Hum Reprod 2012;27:2991–7.
Schwartz SM, Marshall LM, Baird DD. Epidemiologic contributions to understanding the etiology of uterine leiomyomata. Environ Health Perspect
2000;108(Suppl 5):821–7.
Laughlin SK, Baird DD, Savitz DA, Herring AH, Hartmann KE. Prevalence of
uterine leiomyomas in the ﬁrst trimester of pregnancy: an ultrasoundscreening study. Obstet Gynecol 2009;113:630–5.
Klatsky PC, Tran ND, Caughey AB, Fujimoto VY. Fibroids and reproductive
outcomes: a systematic literature review from conception to delivery. Am J
Obstet Gynecol 2008;198:357–66.
Lai J, Caughey AB, Qidwai GI, Jacoby AF. Neonatal outcomes in women with
sonographically identiﬁed uterine leiomyomata. J Matern Fetal Neonatal
Med 2012;25:710–3.
Hartmann KE, Velez Edwards DR, Savitz DA, Jonsson-Funk ML, Wu P,
Sundermann AC, et al. Prospective cohort study of uterine ﬁbroids and
miscarriage risk. Am J Epidemiol 2017;186:1140–8.
Shue S, Radeva M, Falcone T. Comparison of long-term fertility outcomes
after myomectomy: relationship with number of myomas removed. J Minim
Invasive Gynecol 2018;25:1002–8.
Metwally M, Raybould G, Cheong YC, Horne AW. Surgical treatment of ﬁbroids for subfertility. Cochrane Database Syst Rev 2020;1:CD003857.
Khaw SC, Anderson RA, Lui MW. Systematic review of pregnancy outcomes
after fertility-preserving treatment of uterine ﬁbroids. Reprod Biomed Online
2020;40:429–44.
Dubuisson JB, Chapron C, Fauconnier A, Babaki-Fard K. Laparoscopic myomectomy fertility results. Ann N Y Acad Sci 2001;943:269–75.
Management of symptomatic uterine leiomyomas: ACOG Practice Bulletin,
Number 228. Obstet Gynecol 2021;137:e100–15.
Malone LJ. Myomectomy: recurrence after removal of solitary and multiple
myomas. Obstet Gynecol 1969;34:200–3.
Wechter ME, Stewart EA, Myers ER, Kho RM, Wu JM. Leiomyoma-related
hospitalization and surgery: prevalence and predicted growth based on population trends. Am J Obstet Gynecol 2011;205:492.e1–5.

VOL. - NO. - / - 2022
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on March 14, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

9

ORIGINAL ARTICLE: REPRODUCTIVE SURGERY
26.

27.

28.

29.

30.

31.

32.

33.

34.

35.

36.
37.

38.

39.

40.

41.
42.

43.

44.
45.

10

Jin C, Hu Y, Chen XC, Zheng FY, Lin F, Zhou K, et al. Laparoscopic versus
open myomectomy–a meta-analysis of randomized controlled trials. Eur J
Obstet Gynecol Reprod Biol 2009;145:14–21.
Kotani Y, Tobiume T, Fujishima R, Shigeta M, Takaya H, Nakai H, et al. Recurrence of uterine myoma after myomectomy: Open myomectomy versus
laparoscopic myomectomy. J Obstet Gynaecol Res 2018;44:298–302.
Stewart EA, Faur AV, Wise LA, Reilly RJ, Harlow BL. Predictors of subsequent
surgery for uterine leiomyomata after abdominal myomectomy. Obstet Gynecol 2002;99:426–32.
Reed SD, Newton KM, Thompson LB, McCrummen BA, Warolin AK. The
incidence of repeat uterine surgery following myomectomy. J Womens
Health (Larchmt) 2006;15:1046–52.
Barrett ML, Weiss AJ, Stocks C, Steiner CA, Myers ER. Procedures to treat
benign uterine ﬁbroids in hospital inpatient and hospital-based ambulatory
surgery settings, 2013, HCUP Statistical Brief #200. January 2016. Rockville,
MD: Agency for Healthcare Research and Quality; 2016.
Hartmann KE, Fonnesbeck C, Surawicz T, Krishnaswami S, Andrews JC,
Wilson JE, et al. Management of uterine ﬁbroids. Comparative Effectiveness
Review No. 195 (Prepared by the Vanderbilt Evidence-based Practice Center
under Contract No. 290-2015-00003-I.) AHRQ Publication No. 17(18)EHC028-EF. Rockville, MD: Agency for Healthcare Research and Quality;
2017.
Stentz NC, Cooney LG, Sammel M, Shah DK. Changes in myomectomy practice after the US Food and Drug Administration Safety communication on
power morcellation. Obstet Gynecol 2017;129:1007–13.
Barrett ML, Weiss AJ, Stocks C, Steiner CA, Myers ER. Procedures to treat
benign uterine ﬁbroids in hospital inpatient and hospital-based ambulatory
surgery settings, 2013: Statistical Brief #200. Healthcare Cost and Utilization
Project (HCUP) Statistical Briefs. Rockville (MD)2006.
Matsushita T, Sekizawa A, Jacobs LK. Racial disparities in response to a US
Food and Drug Administration safety communication regarding the use of
power morcellation for the treatment of uterine leiomyoma. J Minim Invasive Gynecol 2020;27:178–85.e1.
Practice Committee of the American Society for Reproductive Medicine.
Electronic address Aao, Practice Committee of the American Society for
Reproductive M. Removal of myomas in asymptomatic patients to improve
fertility and/or reduce miscarriage rate: a guideline. Fertil Steril 2017;108:
416–25.
Brady PC, Stanic AK, Styer AK. Uterine ﬁbroids and subfertility: an update on
the role of myomectomy. Curr Opin Obstet Gynecol 2013;25:255–9.
Lebovitz O, Orvieto R, James KE, Styer AK, Brown DN. Predictors of reproductive outcomes following myomectomy for intramural ﬁbroids. Reprod
Biomed Online 2019;39:484–91.
Gavai M, Berkes E, Lazar L, Fekete T, Takacs ZF, Urbancsek J, et al. Factors
affecting reproductive outcome following abdominal myomectomy. J Assist
Reprod Genet 2007;24:525–31.
Kelly BA, Bright P, Mackenzie IZ. Does the surgical approach used for myomectomy inﬂuence the morbidity in subsequent pregnancy? J Obstet Gynaecol 2008;28:77–81.
Pinto Pabon I, Magret JP, Unzurrunzaga EA, Garcia IM, Catalan IB, Cano
Vieco ML. Pregnancy after uterine ﬁbroid embolization: follow-up of 100
patients embolized using tris-acryl gelatin microspheres. Fertil Steril 2008;
90:2356–60.
Sinclair D, Gaither K, Mason TC. Fertility outcomes following myomectomy
in an urban hospital setting. J Natl Med Assoc 2005;97:1346–8.
Surrey ES, Minjarez DA, Stevens JM, Schoolcraft WB. Effect of myomectomy
on the outcome of assisted reproductive technologies. Fertil Steril 2005;83:
1473–9.
Vimercati A, Scioscia M, Lorusso F, Laera AF, Lamanna G, Coluccia A, et al.
Do uterine ﬁbroids affect IVF outcomes? Reprod Biomed Online 2007;15:
686–91.
Metwally M, Cheong YC, Horne AW. Surgical treatment of ﬁbroids for subfertility. Cochrane Database Syst Rev 2012;11:CD003857.
Stewart EA, Laughlin-Tommaso SK, Catherino WH, Lalitkumar S, Gupta D,
Vollenhoven B. Uterine ﬁbroids. Nat Rev Dis Primers 2016;2:16043.

46.

47.

48.

49.

50.

51.

52.
53.
54.
55.
56.

57.

58.
59.
60.

61.
62.

63.

64.

65.

66.
67.

68.

Stewart EA, Lytle BL, Thomas L, Wegienka GR, Jacoby V, Diamond MP, et al.
The Comparing Options for Management: PAtient-centered REsults for
Uterine Fibroids (COMPARE-UF) registry: rationale and design. Am J Obstet
Gynecol 2018;219:95.e1–10.
Spitzer RL, Kroenke K, Williams JB. Validation and utility of a self-report
version of PRIME-MD: the PHQ primary care study. primary care evaluation
of mental disorders. Patient Health Questionnaire. JAMA 1999;282:1737–
44.
Kroenke K. Patients presenting with somatic complaints: epidemiology, psychiatric comorbidity and management. Int J Methods Psychiatr Res 2003;12:
34–43.
Heinemann K, Ruebig A, Potthoff P, Schneider HP, Strelow F,
Heinemann LA, et al. The Menopause Rating Scale (MRS) scale: a methodological review. Health Qual Life Outcomes 2004;2:45.
Zollner YF, Acquadro C, Schaefer M. Literature review of instruments to
assess health-related quality of life during and after menopause. Qual Life
Res 2005;14:309–27.
Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K,
Gonzalves SM. The UFS-QOL, a new disease-speciﬁc symptom and healthrelated quality of life questionnaire for leiomyomata. Obstet Gynecol
2002;99:290–300.
Li F, Morgan KL, Zaslavsky AM. Balancing covariates via propensity score
weighting. J Am Stat Assoc 2018;113:390–400.
Li F, Thomas LE, Li F. Addressing extreme propensity scores via the overlap
weights. Am J Epidemiol 2019;188:250–7.
Austin PC, White IR, Lee DS, van Buuren S. Missing Data in Clinical Research:
A tutorial on multiple imputation. Can J Cardiol 2021;37:1322–31.
Harrell FE Jr, Califf RM, Pryor DB, Lee KL, Rosati RA. Evaluating the yield of
medical tests. JAMA 1982;247:2543–6.
American College of Obstetricians Gynecologists' Committee on practice
bulletins-gynecology. management of symptomatic uterine leiomyomas:
ACOG Practice Bulletin, Number 228. Obstet Gynecol 2021;137:
e100–15.
Burke CT, Funaki BS, Ray CE Jr, Kinney TB, Kostelic JK, Loesberg A, et al. ACR
Appropriateness Criteria on treatment of uterine leiomyomas. J Am Coll Radiol 2011;8:228–34.
Berkowitz GS, Blackmore-Prince C, Lapinski RH, Savitz DA. Risk factors for
preterm birth subtypes. Epidemiology 1998;9:279–85.
Goldenberg RL, Culhane JF, Iams JD, Romero R. Epidemiology and causes of
preterm birth. Lancet 2008;371:75–84.
Reddy UM, Wapner RJ, Rebar RW, Tasca RJ. Infertility, assisted reproductive
technology, and adverse pregnancy outcomes: executive summary of a National Institute of Child Health and Human Development workshop. Obstet
Gynecol 2007;109:967–77.
Luke B, Brown MB. Elevated risks of pregnancy complications and adverse
outcomes with increasing maternal age. Hum Reprod 2007;22:1264–72.
Basso O, Baird DD. Infertility and preterm delivery, birthweight, and
Caesarean section: a study within the Danish National Birth Cohort. Hum
Reprod 2003;18:2478–84.
Wise LA, Mikkelsen EM, Sorensen HT, Rothman KJ, Hahn KA, Riis AH, et al.
Prospective study of time to pregnancy and adverse birth outcomes. Fertil
Steril 2015;103:1065–73.
Messerlian C, Maclagan L, Basso O. Infertility and the risk of adverse pregnancy outcomes: a systematic review and meta-analysis. Hum Reprod
2013;28:125–37.
Dolmans MM, Isaacson K, Zhang W, Gordts S, Munro MG, Stewart EA, et al.
Intramural myomas more than 3-4 centimeters should be surgically removed
before in vitro fertilization. Fertil Steril 2021;116:945–58.
Munro MG. Uterine polyps, adenomyosis, leiomyomas, and endometrial
receptivity. Fertil Steril 2019;111:629–40.
Tanos V, Balami S, Lingwood L. Junctional zone endometrium alterations in
gynecological and obstetrical disorders and impact on diagnosis, prognosis
and treatment. Curr Opin Obstet Gynecol 2019;31:418–27.
Tanos V, Lingwood L, Balami S. The importance of the junctional zone of the
endometrium in human reproduction. Hum Fertil (Camb) 2020:1–9.

VOL. - NO. - / - 2022
Downloaded for Anonymous User (n/a) at Henry Ford Hospital / Henry Ford Health System (CS North America) from ClinicalKey.com by
Elsevier on March 14, 2022. For personal use only. No other uses without permission. Copyright ©2022. Elsevier Inc. All rights reserved.

